The innate immune factor RPRD2/REAF and its role in the Lv2 restriction of HIV
mBio · 2023
DOI: 10.1128/mbio.02572-21 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mBio, 2023. Verfasst von Kathryn A Jackson-Jones und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammation Research, Institute of Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, HIV-2, Immunity, Innate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, UKRI | Medical Research Council (MRC).
Abstract (Originalsprache)
Intracellular innate immunity involves co-evolved antiviral restriction factors that specifically inhibit infecting viruses. Studying these restrictions has increased our understanding of viral replication, host-pathogen interactions, and pathogenesis, and represent potential targets for novel antiviral therapies. Lentiviral restriction 2 (Lv2) was identified as an unmapped early-phase restriction of HIV-2 and later shown to also restrict HIV-1 and simian immunodeficiency virus. The viral determinants of Lv2 susceptibility have been mapped to the envelope and capsid proteins in both HIV-1 and HIV-2, and also viral protein R (Vpr) in HIV-1, and appears dependent on cellular entry mechanism. A genome-wide screen identified several likely contributing host factors including members of the polymerase-associated factor 1 (PAF1) and human silencing hub (HUSH) complexes, and the newly characterized regulation of nuclear pre-mRNA domain containing 2 (RPRD2). Subsequently, RPRD2 (or RNA-associated early-stage antiviral factor) has been shown to be upregulated upon T cell activation, is highly expressed in myeloid cells, binds viral reverse transcripts, and potently restricts HIV-1 infection. RPRD2 is also bound by HIV-1 Vpr and targeted for degradation by the proteasome upon reverse transcription, suggesting RPRD2 impedes reverse transcription and Vpr targeting overcomes this block. RPRD2 is mainly localized to the nucleus and binds RNA, DNA, and DNA:RNA hybrids. More recently, RPRD2 has been shown to negatively regulate genome-wide transcription and interact with the HUSH and PAF1 complexes which repress HIV transcription and are implicated in maintenance of HIV latency. In this review, we examine Lv2 restriction and the antiviral role of RPRD2 and consider potential mechanism(s) of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Inflammation Research, Institute of Regeneration and Repair, The University of Edinburgh, Edinburgh, United Kingdom.
- Division of Infectious Diseases & Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
- ZJU-UoE Institute, Zhejiang University, Haining, China.
ORCID-Profile: Kathryn A Jackson-Jones, Áine McKnight, Richard D Sloan
Förderung
- Wellcome Trust
- Medical Research Council
- UKRI | Medical Research Council (MRC)
Zitieren
APA
Jackson-Jones, K. A., McKnight, Á., & Sloan, R. D. (2023). The innate immune factor RPRD2/REAF and its role in the Lv2 restriction of HIV. mBio. https://doi.org/10.1128/mbio.02572-21
Vancouver
Jackson-Jones KA, McKnight Á, Sloan RD. The innate immune factor RPRD2/REAF and its role in the Lv2 restriction of HIV. mBio. 2023. doi:10.1128/mbio.02572-21
BibTeX
@article{JacksonJones2023,
author = {Jackson-Jones, Kathryn A and McKnight, Áine and Sloan, Richard D},
title = {The innate immune factor RPRD2/REAF and its role in the Lv2 restriction of HIV},
journal = {mBio},
year = {2023},
doi = {10.1128/mbio.02572-21}
}
EUVIMED